Open AccessEffect of Tyrosine Kinase Inhibition by Imatinib Mesylate on Mast Cell Tumors in Dogs
Author(s) -
Isotani M.,
Ishida N.,
Tominaga M.,
Tamura K.,
Yagihara H.,
Ochi S.,
Kato R.,
Kobayashi T.,
Fujita M.,
Fujino Y.,
Setoguchi A.,
Ono K.,
Washizu T.,
Bonkobara M.
Publication year - 2008
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.2008.00132.x
Subject(s) - imatinib mesylate , medicine , imatinib , mesylate , tyrosine kinase inhibitor , tyrosine kinase , exon , cancer research , pharmacology , cancer , receptor , biology , chemistry , genetics , myeloid leukemia , organic chemistry , gene
Background: Imatinib mesylate is a small molecule targeted at dysregulated protein‐tyrosine kinase. Mutation of c‐kit exon 11, which induces constitutive phosphorylation of KIT, is one of the mechanisms for the development or progression of mast cell tumor (MCT) in dogs. The purpose of this study was to examine the therapeutic potential of imatinib mesylate in canine MCT. Hypothesis: Imatinib mesylate has activity against MCT in dogs, and response to treatment can be correlated to presence of mutation within exon 11 of c‐kit. Animals: Twenty‐one dogs with MCT with gross tumor burden and median tumor size of 7.2 cm (range, 1.0–25.3 cm) before treatment. Methods: Tumors were analyzed for mutation of c‐kit exon 11. Imatinib mesylate was administered PO to the dogs at a dose of 10 mg/kg daily for 1–9 weeks. Results: Ten of 21 dogs (48%) had some beneficial response to imatinib mesylate treatment within 14 days of treatment initiation. All 5 dogs with a demonstrable c‐kit mutation in exon 11 responded to the drug (1 complete remission, 4 partial remission). Conclusions and Clinical Importance: Imatinib mesylate has clinical activity against MCT in dogs. Response could not be predicted based on presence of absence of a mutation in exon 11 of c‐kit.